The content on this site is intended for healthcare professionals only
Dr Rodón talks to ecancertv at ESMO 2016 about the innovative uses of a new kinase inhibitor for angiogenesis and fibroblast growth factor receptors.
He also discusses how some tumours with genetic alterations could benefit from the use of this new class of drug.
ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Psychological issues in familial cancer
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
Research highlights in gastrointestinal tumours
GIST tumours and soft tissue sarcomas
A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM
EHA 2024: Multiple myeloma roundup
Relapsed refractory multiple myeloma
